Thymagen Preclinical

What It Is

Thymagen — more commonly called Thymogen in the Russian pharmaceutical registry — is a synthetic dipeptide consisting of L-glutamic acid and L-tryptophan linked by an amide bond (Glu-Trp; EW, one-letter code). Along with Vilon (Lys-Glu; KE), Thymagen is one of the two simplest members of the Khavinson bioregulator system — a remarkable biological property given its minimal molecular size (only two residues, ~333 Da). It is soluble, stable, and bioavailable by multiple routes.

The historical origin of Thymagen is specific: the molecule was isolated from the natural calf-thymus peptide complex known as Thymalin by reversed-phase high-performance liquid chromatography (RP-HPLC) by the Morozov-Khavinson group at the Saint Petersburg Institute of Bioregulation and Gerontology. After identification, it was synthesized chemically and characterized for biological activity, and a pharmaceutical preparation — Thymogen — was designed on the basis of the synthetic dipeptide. Both Thymalin (the complex) and Thymogen (the isolated dipeptide) remain in Russian clinical use.

Nomenclature is slightly confusing in the international community: the Russian pharmaceutical is Thymogen, which is the same molecule sometimes called Thymagen in Western research-peptide marketing. The underlying compound is the same Glu-Trp dipeptide; the naming difference is commercial and linguistic. Thymagen is also occasionally confused with Thymalin (the full peptide complex) and with Thymulin (a distinct thymic nonapeptide bound to zinc). These three are not interchangeable.

Thymagen sits within the Khavinson framework as an "immunocorrector" intended to restore balanced T-cell function in states of secondary immunodeficiency — not as a pure immunostimulant. The theoretical framing is that an appropriately functioning immune system requires correct T-cell subset balance, appropriate cytokine signaling, and adequate thymic education of naive T cells; Thymagen is proposed to support these processes without blanket-activating an already-competent immune system. In Russian clinical practice it has been used across chronic bronchopulmonary conditions, post-surgical immune support, radiation- or chemotherapy-induced immunosuppression, and as a general adjunct in geriatric and pediatric immune practice.

Mechanism of Action

Thymagen's mechanism of action combines two proposed components: the broader Khavinson peptide-DNA framework (shared with all short Khavinson peptides) and specific immunomodulatory effects documented in the Morozov-Khavinson Western-indexed literature.

• T-cell differentiation (Kozlov & Khavinson, Int Immunopharmacol 1997) — Thymagen (EW dipeptide) and the natural Thymalin complex both activate T-cell differentiation in vitro. Kozlov and Khavinson (1997) demonstrated parallel activity in T-cell-receptor recognition of peptide-MHC complexes and in intracellular cyclic nucleotide composition.
• Cytokine secretion (IL-2, IFN) — Per the same foundational publication, both natural and synthetic thymic peptides induce changes in cytokine secretion from blood lymphocytes, notably interleukin-2 and interferon. This is consistent with an immunomodulatory rather than purely stimulatory profile.
• Neutrophil chemotaxis and phagocytosis — Synthetic dipeptides including Thymagen activate neutrophil chemotaxis and phagocytic capacity in vitro — a functional effect not limited to T-cell lineages.
• THP-1 monocyte / macrophage regulation (Khavinson group, 2022; PMC8999041) — In the THP-1 human monocytic cell line capable of differentiating into macrophages, Thymogen (EW) and related Khavinson peptides regulated proliferation and inflammation-related gene expression. Provides a modern cellular framework for the Khavinson theory.
• Bidirectional immunomodulation — Consistent with the broader Khavinson framework, Thymagen is proposed to normalize — rather than stimulate — immune function. Active in states of impaired immunity, less active in systems with already-appropriate function. This framing distinguishes the compound from pure immunostimulants.
• CD4 / CD8 balance — Russian clinical-tradition reports describe normalization of CD4/CD8 T-cell ratios in immunodeficient populations treated with Thymogen courses. Mechanism is proposed to be at the level of thymic T-cell education and peripheral T-cell selection.
• Proposed peptide-DNA interaction (Khavinson framework) — Across the Khavinson peptide family, short peptides are proposed to cross cell and nuclear membranes and bind specific DNA promoter regions, thereby modulating gene expression. For Thymagen, target-gene sets are proposed to involve T-cell differentiation and lymphocyte activation markers. This peptide-DNA interaction model is specific to the Khavinson group's framework and has not been independently validated in mainstream immunology.
• Anti-neoplastic signal (Anisimov, Miretskii, Morozov, Khavinson et al., 1989) — Early Russian-language work reported inhibition of esophageal and forestomach tumor development induced by N-nitrososarcosine ethyl ester in rats treated with Thymogen. This represents a chemoprevention signal in a classical rodent carcinogenesis model; translational relevance to humans is undefined.
• Ischemia-reperfusion modulation — A 1997 Russian publication (Eksp Klin Farmakol; PMID 9324392) reported Thymogen effects on ischemia-reperfusion physiology in the heart, suggesting bioactivity beyond the immune system.
• Oral bioavailability — As a short, water-soluble dipeptide, Thymagen can be absorbed intact across the gastric and intestinal epithelium via peptide-transporter mechanisms (PEPT1-family transporters handle dipeptides as preferential substrates). This provides theoretical support for oral dosing — though specific PK data in humans is sparse.

What the Research Shows

Thymagen / Thymogen has one of the larger research footprints of the Khavinson bioregulator family, though the footprint remains heavily Khavinson-group-sponsored. Key studies:

• Kozlov VA, Khavinson VK (Int Immunopharmacol 1997) — "Natural and synthetic thymic peptides as therapeutics for immune dysfunction." Foundational Western-indexed characterization of Thymalin and Thymogen. Demonstrated parallel bioactivity of natural and synthetic thymic peptides in T-cell differentiation, peptide-MHC recognition, cytokine secretion, and phagocyte function.
• L-Glu-L-Trp dipeptide anti-aging and anti-carcinogenesis (Anisimov-Khavinson group; PMID 11707921) — "Immunomodulatory synthetic dipeptide L-Glu-L-Trp slows down aging and inhibits spontaneous carcinogenesis in rats." A rodent chronic administration study reporting increased lifespan and reduced spontaneous tumor incidence in treated animals. Methodology and group-sizes are typical of the Khavinson program.
• Bespalov et al. (Eksp Onkol 1989; PMID 2759010) — Inhibiting effect of Thymogen on development of N-nitrososarcosine-induced esophageal and forestomach tumors in rats. Russian-language chemoprevention paper.
• Zhuk & Galenok (Ter Arkh 1996; PMID 9026934) — "Thymogen in the treatment of type-1 diabetes mellitus." Russian clinical paper describing adjunctive Thymogen use in autoimmune diabetes — representative of the Russian immune-disease clinical tradition.
• Khmel'nitskii et al. Russian thymic peptide histology / pathology series — Multiple Russian-language publications characterizing Thymalin-fraction biology and clinical use.
• Ischemia-reperfusion paper (Eksp Klin Farmakol 1997;60(3):27-9; PMID 9324392) — "The effect of thymogen on the heart in ischemia and reperfusion." Rodent cardiac ischemia / reperfusion model showing protective effects.
• THP-1 monocyte/macrophage regulation (Khavinson group 2022; PMC8999041) — "Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line." Modern mechanistic study in human cell line evaluating five Khavinson peptides (Epitalon, Vilon, Thymogen, Thymalin, Chonluten) as regulators of inflammation and proliferation.
• Khavinson VK, Bondarev IE, Butyugov AA (Bull Exp Biol Med 2003;135(6):590-592; PMID 12937678) — Epithalon (sister Khavinson peptide) induces telomerase activity — establishes the methodological style of Khavinson group peptide-effect papers.
• Anisimov & Khavinson (Biogerontology 2010; PMID 19415510) — "Peptide bioregulation of aging: results and prospects." Review paper covering the broader Khavinson program including Thymogen.
• Khavinson VK et al. (Bull Exp Biol Med 2020; PMID 33237528) — Thymalin-derived peptides and hematopoietic stem cell differentiation: modern extension of the Thymalin / Thymogen framework.
• Khavinson VK et al. (2021; PMID 33575961) — "Results and Prospects of Using Activator of Hematopoietic Stem Cell Differentiation in Complex Therapy for Patients with COVID-19." Proposes thymus-derived peptides (including Thymagen / Thymogen) for T-cell restoration in COVID-19 contexts.
• Russian pharmacopoeia registration — Thymogen is registered as a pharmaceutical in Russia and has been used in clinical practice for decades. Formulations include parenteral (IM / SubQ), intranasal spray, and oral.

Human Data

Summary of Thymagen's human evidence base:

• Russian clinical tradition — Multi-decade use in Russian immunology, infectious disease, and geriatric practice. Registered as Thymogen (pharmaceutical) and widely dispensed for secondary immunodeficiency, chronic bronchopulmonary disease, post-surgical immune support, and chemotherapy / radiotherapy adjunct.
• Type-1 diabetes adjunct (Zhuk & Galenok, 1996; PMID 9026934) — Small Russian clinical cohort reporting adjunct Thymogen use in type-1 diabetes with immunological monitoring. Cohort size and methodology typical of Russian clinical tradition.
• Recurrent respiratory infections — Russian practice literature in pediatric and adult populations with recurrent upper respiratory infections, reporting reduced infection frequency and improved T-cell indices after Thymogen courses.
• COVID-19 thymic-peptide adjunct (Khavinson 2021; PMID 33575961) — Review proposal for thymus-derived peptides (Thymalin / Thymagen) as T-cell restoration adjuncts in severe COVID-19, based on the broader Khavinson clinical tradition. Not a randomized controlled trial; a rationale paper.
• No Western randomized placebo-controlled trials — PubMed and ClinicalTrials.gov do not list registered RCTs of Thymagen / Thymogen as a stand-alone intervention indexed in Western literature. All human evidence remains from Russian clinical tradition.
• No pharmacokinetic data in Western literature — Formal PK studies of intact EW dipeptide after oral, intranasal, or SubQ administration in humans are not published in PubMed-indexed English-language journals.
• Long safety record — Decades of Russian use across adults and children without major safety signals. Consistent with the broader Khavinson peptide-class practical safety track record.
• Self-reported community use — International research-peptide community uses Thymagen / Thymogen as an oral or intranasal immune-support bioregulator, typically in short Khavinson-style courses. These reports are anecdotal and uncontrolled.

Dosing from the Literature

Dosing below reflects Khavinson-tradition Russian protocols and community practice. These are not validated by Western RCTs.

Reconstitution & Storage

Thymagen is typically supplied in three forms in the global market: oral capsules (10 mg), intranasal spray (standardized micrograms per actuation), and lyophilized peptide powder for research SubQ use.

• Reconstitution (SubQ lyophilized) — Inject BAC water slowly at 45°; swirl gently. Dissolves within 30–60 seconds to a clear colorless solution.
• Storage (reconstituted) — 2–8°C refrigerated; use within 21–28 days. Do not freeze reconstituted solution.
• Oral administration — Morning on empty stomach per Khavinson tradition; allow 20–30 minutes before eating. Some practitioners use sublingual dissolution.
• Intranasal administration — Standard Russian Thymogen spray dispensing. Alternate nostrils; avoid immediately after blowing the nose.
• Needle (SubQ) — 29G–31G half-inch insulin syringe. Small volumes.
• Inspection — Discard if cloudy, discolored, or showing particulate.
• Purity — As a dipeptide, EW is easy to synthesize at high purity. Independent third-party COA (HPLC + mass spec) is the practical floor for due diligence.

→ Use the Kalios Dosing Calculator for SubQ conversions

Side Effects & Risks

Thymagen / Thymogen has a long practical safety record in Russian clinical use. Known risk profile:

• Extremely well-tolerated — Simple dipeptide of common amino acids. Russian clinical tradition reports few serious adverse events across decades of use.
• Oral tolerability — Well-tolerated. Rare reports of mild GI discomfort.
• Intranasal tolerability — Occasional mild nasal irritation. Self-limited.
• SubQ / IM tolerability — Mild local reactions (erythema, transient tenderness). Self-limited within 24 hours.
• Autoimmune theoretical concern — Any T-cell-modulating peptide could theoretically affect autoimmune disease activity. Use in active autoimmune disease (rheumatoid arthritis flares, lupus, MS, autoimmune thyroid disease in active thyrotoxic or myxedematous phases) should be discussed with an immunology-aware clinician.
• Active malignancy — T-cell modulation could in principle affect tumor immunology in ways that are difficult to predict; conservative practice is to avoid in active or recently treated malignancy until further clinical characterization exists.
• Organ transplant — Not appropriate for post-transplant patients on maintenance immunosuppression; T-cell modulation could interact with transplant rejection biology.
• Pregnancy and lactation — Contraindicated in the absence of specific safety data.
• Pediatric use — Used in pediatric Russian practice under clinician supervision; community self-dosing in children is not advisable without medical oversight.
• Drug interactions — Largely uncharacterized. Caution advised with biologic immunotherapies, chronic corticosteroids, and immunosuppressants.
• Purity risk — Lot-to-lot variability in gray-market supply; third-party COA is the practical floor for due diligence.
• Not a substitute for evidence-based immune care — In any clinically significant infection, immunodeficiency, or autoimmune condition, evidence-based immunology evaluation and treatment are appropriate; Thymagen should not replace validated care.

Bloodwork & Monitoring

No formal monitoring protocol is specified. Reasonable research-context monitoring for informed use:

• Baseline CBC with differential — Lymphocyte subset counts establish the starting immunologic baseline.
• Lymphocyte subsets (if relevant) — CD4, CD8, CD4/CD8 ratio, NK cells. Standard secondary-immunodeficiency workup if immunologic concern exists.
• Total immunoglobulins — IgG, IgA, IgM baseline; repeat at 12 weeks if a specific immune-deficiency concern is being tracked.
• CMP — Standard liver / kidney function baseline.
• hsCRP / ESR — Inflammatory-marker baseline.
• Thyroid panel (TSH + free T4) — Thyroid autoimmunity is a common comorbid consideration when thymic-axis peptides are used.
• Anti-nuclear antibody (ANA) screening — If used in contexts where autoimmune concern exists.
• Symptomatic tracking — Infection frequency, sick-day diaries, and clinician-reported outcome measures for chronic immunologic conditions.

Commonly Stacked With

→ Check compound compatibility in the Stack Builder

Supportive Nutrition & Context

Thymagen's proposed mechanism is immunomodulatory rather than immunostimulatory, and expected magnitude of effect is modest in a basally competent immune system. For users considering Thymagen as part of a broader immune-support strategy, several higher-leverage fundamentals apply first:

• Sleep (7–9 hours) — Chronic sleep restriction measurably impairs T-cell function, NK-cell activity, and vaccine response. Sleep is the single highest-leverage immune-supporting intervention and no bioregulator substitutes for it.
• Vitamin D (target serum 40–60 ng/mL) — Vitamin D deficiency is epidemiologically associated with increased infection risk and is straightforward to correct. Standard dose 2,000–5,000 IU daily to target.
• Zinc (15–25 mg elemental daily; avoid chronic >40 mg) — Zinc status supports thymic function; deficiency produces measurable thymic atrophy and impaired T-cell output. Supplementation above replete-zinc status does not improve immune function further and chronic excess causes copper depletion.
• Protein intake (1.2–1.6 g/kg/day) — Immune function is protein-dependent; malnutrition reliably impairs it. Adequate protein intake is a precondition for any immune-supporting intervention.
• Omega-3 (2 g EPA+DHA daily) — Supports balanced inflammation and resolution of inflammation.
• Exercise (moderate, regular) — Moderate regular exercise improves immune function; chronic overtraining impairs it. Sustainable baseline activity is the target.
• Stress management — Chronic psychological stress impairs T-cell function via sustained cortisol elevation. No peptide bioregulator fully overcomes chronic stress; the stress is the higher-leverage target.
• Smoking cessation — Chronic smoking measurably impairs mucosal and systemic immunity. Cessation restores function substantially within months.
• Alcohol moderation — Chronic heavy alcohol intake impairs T-cell function and phagocyte function.
• Things to avoid — Chronic high-dose corticosteroids, excess iron supplementation in non-deficient individuals, unnecessary antibiotic courses, and chronic untreated infections that mask as "immune weakness."
• Clinical evaluation first — Recurrent serious infections, unexplained fatigue with lymphadenopathy, or any symptom suggestive of primary or secondary immunodeficiency warrants evaluation by an immunology-aware clinician. Bioregulator-class peptides are not a substitute for primary immunodeficiency workup.

What to Expect — Timeline

The following reflects Khavinson-tradition Russian practice expectations. Not a clinical prognosis.

• Day 1–7 (initiation) — Standard 10–20 day oral course or 5–10 day parenteral course begins. Acute subjective change is typically not dramatic.
• Mid-course (day 5–14) — Russian clinical tradition describes some patients reporting improved sense of wellbeing, reduced fatigue, or reduced sick-day frequency in patients with chronic recurrent infections. These are non-specific subjective endpoints.
• End of course — Planned endpoint. Labs (CBC with differential, lymphocyte subsets if clinically relevant) at baseline and end-of-course establish trajectory. Magnitude of measurable change is typically modest.
• Off-cycle — Any benefit is expected to persist for weeks to months. In Russian practice, courses are typically repeated 2–3× per year rather than administered continuously.
• Chronic recurrent respiratory infection context — Russian practice reports reduced infection frequency across a full year with cyclical Thymogen courses combined with baseline immune fundamentals. This is practice-level data, not RCT evidence.
• Non-responders — A meaningful fraction report no clear benefit. Common explanations: placebo-expectation mismatch, product-purity issues, or immune concerns with causes beyond what a bioregulator addresses (primary immunodeficiency, uncontrolled diabetes, chronic corticosteroid use).
• Red flags to stop — Unexpected new symptoms, new rash, new autoimmune-pattern symptoms (joint pain, dry eyes, thyroid-function changes), or any escalating symptom. Stop first, evaluate second.

Regulatory Status

Related Compounds

Peptides people often cross-check against Thymagen:

Next Steps

Key References

1. Kozlov VA, Khavinson VKh. Natural and synthetic thymic peptides as therapeutics for immune dysfunction. Int Immunopharmacol. 1997;19(9-10):501-505. doi:10.1016/S0192-0561(97)00058-1. (Foundational Western-indexed characterization of Thymalin and Thymogen.)
2. Anisimov VN, Khavinson VKh, Morozov VG. Immunomodulatory synthetic dipeptide L-Glu-L-Trp slows down aging and inhibits spontaneous carcinogenesis in rats. Biogerontology. 2001;2(1):47-55. PMID: 11707921. (Chronic rodent dosing — longevity and anti-carcinogenesis signal.)
3. Bespalov VG, Troian DN, Petrov AS, Morozov VG, Khavinson VKh. Ingibiruiushchii effekt timogena na razvitie opukholei pishchevoda i predzheludka, indutsirovannykh etilovym efirom N-nitrozosarkozina u krys [Inhibiting effect of thymogen on the development of tumors of the esophagus and forestomach induced by N-nitrososarcosine ethyl ester in rats]. Eksp Onkol. 1989;11(4):23-26. Russian. PMID: 2759010.
4. Zhuk EA, Galenok VA. Timogen v lechenii sakharnogo diabeta I tipa [Thymogen in the treatment of type-1 diabetes mellitus]. Ter Arkh. 1996;68(10):12-14. Russian. PMID: 9026934.
5. Khmelnitskii OK, Iakovlev GM, Belianin VL, Khavinson VKh, Morozov VG, Deigin VI. Vliianie timogena na sostoianie serdtsa pri ishemii i reperfuzii [The effect of thymogen on the heart in ischemia and reperfusion]. Eksp Klin Farmakol. 1997;60(3):27-29. Russian. PMID: 9324392.
6. Khavinson VK, Linkova NS, Kukanova EO, Bolshakova AV, Gainullina AN, Tendler SM, Morozov VG, Tarnovskaya SI, Vanyushin BF, Shataeva LK, Bakaeva ZV. Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line. Int J Mol Sci. 2022. PMC8999041. (Modern mechanistic study including Thymogen / Thymagen.)
7. Khavinson VK, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590-592. PMID: 12937678. (Methodological style of Khavinson mechanistic papers.)
8. Khavinson VK. Peptides and Ageing. Neuroendocrinol Lett. 2002;23 Suppl 3:11-144. PMID: 12374906. (Foundational review of the Khavinson peptide bioregulator program.)
9. Khavinson VK, Malinin VV. Gerontological Aspects of Genome Peptide Regulation. Basel: Karger; 2005.
10. Anisimov VN, Khavinson VKh. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139-149. PMID: 19415510.
11. Khavinson VK, Linkova NS, Kukanova EO, Bolshakova AV, Gainullina AN. Results and Prospects of Using Activator of Hematopoietic Stem Cell Differentiation in Complex Therapy for Patients with COVID-19. Stem Cell Rev Rep. 2021. PMID: 33575961.
12. Khavinson VK, Linkova NS, Trofimov AV, Polyakova VO, Sevostyanova NN, Kvetnoy IM. Morphofunctional fundamentals for peptide regulation of aging. Biogerontology. 2011;12(2):95-106. (Supporting mechanistic framework.)
13. Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide regulation of cell differentiation, gene expression, and protein synthesis. Bull Exp Biol Med. 2021;170(5):707-711.
14. Morozov VG, Khavinson VKh. Natural and synthetic thymic peptides: isolation, structure, and biological activity. Int J Immunopharmacol. 1997;19(9-10):501-505. (Original characterization.)
15. FDA. Bulk Drug Substances Nominated for Use in Compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act. FDA.gov. Updated 2025–2026 (Thymagen / EW dipeptide / Thymogen not listed).